结外NK/T细胞淋巴瘤-鼻型中PRDM1表达及其与PI3K/AKT通路活化的关系
该研究检测了10例结外NK/T细胞淋巴瘤-鼻型(EN-NK/T-NT)组织及YT、NKL、NK92细胞系中PRDM1与p-AKT表达,发现PI3K/AKT通路相关基因在EN-NK/T-NT中高表达,p-AKT在YT细胞高表达,LY294002可剂量依赖性上调YT细胞PRDM1和PTEN,并抑制YT细胞增殖、增加G1期比例。
要点
- PI3K/AKT通路相关基因在EN-NK/T-NT组织中高表达(P<0.05)。
- p-AKT在PRDM1阳性YT细胞高表达,在NK92和NKL细胞低表达或不表达。
- LY294002(20 μmol/L)作用48 h使YT细胞增殖率降至58.18%,G1期比例升至76.93%。
核心结论
- EN-NK/T-NT中PI3K/AKT通路活化与PRDM1阳性表达相关,抑制PI3K/AKT通路可能对PRDM1阳性EN-NK/T-NT具有显著治疗潜力。
研究设计与样本
- 以10例EN-NK/T-NT患者病理组织标本和PRDM1阳性YT细胞系、PRDM1缺失NKL及NK92细胞系为研究对象,采用免疫细胞化学、Western blot、NanoString基因表达谱、MTS法和流式细胞术检测。
主要发现
- NanoString基因表达谱显示PRDM1阳性组PI3K/AKT信号通路IL-7、BRCA1、ITGA8、IL2RB、FASLG、CDK2、COL27A1、CSF3R、KITLG、IL-6表达明显高于对照组,差异均有统计学意义(P值均<0.05)。
- 免疫细胞化学和Western blot显示p-AKT在YT细胞系中高表达,而在NK92和NKL细胞中低表达或不表达。
- Western blot显示PI3K/AKT通路抑制剂LY294002作用24 h后YT细胞PRDM1和PTEN表达水平升高,且呈剂量依赖性。
- LY294002(20 μmol/L)作用48 h后,与对照组比较,YT细胞增殖率明显降低(100.00%对58.18%,t=-12.770,P=0.006),G1期细胞比例明显增高(30.05%对76.93%,t=11.570,P<0.001),差异均有统计学意义。
- NKL细胞与对照组比较细胞增殖和细胞周期的差异均无统计学意义(P值均>0.05)。
关键数值与推荐
- PI3K/AKT通路相关基因(IL-7、BRCA1、ITGA8、IL2RB、FASLG、CDK2、COL27A1、CSF3R、KITLG、IL-6)在EN-NK/T-NT中高表达,P值均<0.05。
- LY294002(20 μmol/L)作用48 h后YT细胞增殖率为58.18% vs 对照组100.00%(t=-12.770,P=0.006)。
- LY294002(20 μmol/L)作用48 h后YT细胞G1期比例为76.93% vs 对照组30.05%(t=11.570,P<0.001)。
临床怎么用
- 原文结论认为抑制PI3K/AKT通路可能对PRDM1阳性EN-NK/T-NT具有显著治疗潜力。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the expression of PRDM1 and its relationship with PI3K/AKT pathway activation in extranodal NK/T cell lymphoma-nasal type. Methods: Immunocytochemistry and Western blot were used to detect the expression of PRDM1 and p-AKT in 10 EN-NK/T-NT tissue or 3 cell lines (PRDM1-positive YT cell line, PRDM1-negative NKL and NK92 cell lines). Nanostring gene expression profiling technique was used to detect the activation of the PI3K/AKT pathway in normal nasal mucosa, PRDM1-negative and positive EN-NK/T-NT tissue. MTS was used to detect cell proliferation, and flow cytometry was used to detect cell cycle and apoptosis. Results: Nanostring gene expression profiling revealed that genes associated with PI3K/AKT signaling pathway (eg, IL-7, BRCA1, ITGA8, IL2RB, FASLG, CDK2, COL27A1, CSF3R, KITLG and IL-6) were highly expressed in EN-NK/T-NT cases (P<0.05). Also, we found that p-AKT was highly expressed in YT cell line, but lower or not expressed in NK92 and NKL cells. In addition, LY294002, a PI3K/AKT pathway inhibitor, increased PRDM1 and PTEN expression in a dose dependent manner in YT cells. More importantly, YT cell were treated with 20 μmol/L LY294002 48 h, the proliferation rate was significantly decreasing (58.18% vs 100.00%, t=12.770, P=0.006), and the proportion of cells in G(1) phase was significantly increased (30.05% vs 76.93%, t=11.570, P<0.001). However, there was no significant difference in cell proliferation and cell cycle between NKL cells and control group (P>0.05). Conclusion: The activation of PI3K/AKT pathway is positive associated with the expression of PRDM1 in EN-NK/T-NT, and inhibition of PI3K/AKT pathway may have significant therapeutic potential for PRDM1-positive EN-NK/T-NT. 目的: 探讨抑癌基因PRDM1在结外NK/T细胞淋巴瘤-鼻型(EN-NK/T-NT)中的表达及其与PI3K/AKT通路活化的关系。 方法: 以10例EN-NK/T-NT患者病理组织标本和PRDM1阳性细胞系YT细胞、PRDM1缺失细胞系NKL、NK92细胞为研究对象,采用免疫细胞化学和Western blot法检测PRDM1、p-AKT的表达,采用NanoString基因表达谱技术检测PI3K/AKT通路在正常鼻黏膜、PRDM1阴性和阳性EN-NK/T-NT组织中的激活情况,采用MTS法检测YT、NKL和NK92细胞增殖活性,采用流式细胞术检测细胞周期和细胞凋亡。 结果: ①NanoString基因表达谱分析结果显示PRDM1阳性组PI3K/AKT信号通路IL-7、BRCA1、ITGA8、IL2RB、FASLG、CDK2、COL27A1、CSF3R、KITLG、IL-6的表达明显高于对照组,差异均有统计学意义(P值均<0.05)。②免疫细胞化学和Western blot法检测结果显示p-AKT在YT细胞系中高表达,而在NK92和NKL细胞中低表达或不表达。③Western blot法检测结果显示,PI3K/AKT通路抑制剂LY294002作用24 h后YT细胞PRDM1和PTEN的表达水平升高,且呈剂量依赖性。④LY294002(20 μmol/L)作用48 h后,与对照组比较,YT细胞增殖率较对照组明显降低(100.00%对58.18%,t=-12.770,P=0.006),G(1)期细胞比例明显增高(30.05%对76.93%,t=11.570,P<0.001),差异均有统计学意义;但NKL细胞与对照组比较细胞增殖和细胞周期的差异均无统计学意义(P值均>0.05)。 结论: EN-NK/T-NT中PI3K/AKT通路活化与PRDM1阳性表达相关,抑制PI3K/AKT通路有望成为PRDM1阳性EN-NK/T-NT的治疗手段。.
引用
- Liu JM, Liang L, Huang SS, et al. [PRDM1 expression and its relationship with PI3K/AKT pathway activation in extranodal NK/T cell lymphoma-nasal type]. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 30612403. doi:10.3760/cma.j.issn.0253-2727.2018.12.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。